TRX-0237 Methylate

Research use only, not for human use.

TRX-0237 Methylate (LMTX) is a Tau aggregation inhibitor (TAI) with Ki of 0.12 uM for intracellular TAI activity.

TRX-0237 Methylate (LMTX) is a Tau aggregation inhibitor (TAI) with Ki of 0.12 uM for intracellular TAI activity; disrupts paired helical filaments (PHFs) isolated from AD brain tissues at 0.16 uM, delays cellular senescence and enhances key mitochondrial biochemical pathways; demonstrates activities in clinical trials in Alzheimer's disease (AD) with drugs targeting β-amyloid accumulation in the brain.Alzheimer Disease Phase 3 Clinical(In Vitro):Leucomethylene blue (100 nM, 48 h) mesylate not only decreases the tau and p-tau expression levels, but also reversed the promoting effects of Aβ25-35 on orexin A and adenosine A1R expression levels.

Western Blot AnalysisCell Line:Human SH-SY5Y cell line.Concentration:100 nM.Incubation Time:48 h.Result:Aβ25-35 and TRx 0237 co-treatment significantly reversed the promoting effects of Aβ25-35 on tau, p-tau, orexin A and adenosine A1R expression.

——

LMTX | Hydromethylthionine | Methylene blue

Others

Amyloids

Tau aggregation

Neurological Disease

Alzheimer Disease

1236208-20-0

379.493

C17H21N3O3S2

>98% (HPLC)

H2O : ≥ 31 mg/mL 64.91 mM

CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O

3,7-bis(dimethylamino)phenothiazin-5-ium methanesulfonate

(-20℃)

With Ice Pack

≥ 2 years